Evolution of analogical reasoning in children: follow-up from six to eleven years old

The aim of this study is to establish the time and period of development of Analogical Reasoning (AR) and evaluate its independence and performance with respect to the age. We performed a longitudinal cohort study of two age groups and six annual follow-up phases from each one (2000-2005, 2001-2006) in six to eleven years-old children in the city of Huanuco (Peru) with a sample of 167 children (first stage), and N=121 (sixth stage). The Raven’s progressive matrices test, coloured version, was applied individually without time limits. Results indicate that AR development occurs in a constant and late way from seven to eleven years-old children, and also that there is independence between the ability of AR and the children age. We discuss the importance of knowledge in the relationships between analogies topics, adjusted to the age, as a mediating factor in the development of AR.

Clinical experience of clobazam as add-on treatment in a cohort of adults with epilepsy

Objective: Epilepsy is a common neurologic disorder affecting 1% of the world population with one-third of these patients failing to have seizure control for more than one year. Clobazam is a long-acting benzodiazepine used worldwide for the treatment of epilepsy. This antiepileptic drug has demonstrated great clinical benefits with mild side effects. The objective of this study was to better understand the efficacy of clobazam treatment on adult patients with refractory epilepsy. Design: A retrospective review of 44 adult patients with diagnosis of epilepsy that were seen at our Epilepsy Clinic between January 2014 and May 2015. Setting: An outpatient epilepsy clinic at the Hospital Universitario Fundación Santa Fe de Bogota, Colombia. Participants: 44 adult patients with diagnosis of epilepsy. Measurements: Seizure frequency, adverse effects and the use of concomitant AEDs were reviewed in each of the patient´s clinical charts. Results: The responder rate of patients with clobazam was 52% at 3 months, 50% at 6 months and 55% at 12 month. Seizure freedom rates at 3, 6 and 12 months were 18%, 25% and 25% respectively. Clobazam related adverse events occurred only in four patients (9%) at the end of the twelve months with somnolence being the most common. Conclusion: These findings suggest that clobazam treatment in adult patients with focal or generalized epilepsy is effective and safe. Its use should be considered early when first-line agents fail to provide seizure control.